Prothena (NASDAQ:PRTA) Reaches New 12-Month Low at $21.31

Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s stock price hit a new 52-week low on Tuesday . The stock traded as low as $21.31 and last traded at $21.96, with a volume of 17476 shares trading hands. The stock had previously closed at $21.99.

Analysts Set New Price Targets

Several equities analysts have weighed in on PRTA shares. Royal Bank of Canada dropped their price objective on Prothena from $36.00 to $35.00 and set a "sector perform" rating on the stock in a research note on Friday, February 16th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a research report on Wednesday, April 10th. Oppenheimer decreased their target price on Prothena from $98.00 to $80.00 and set an "outperform" rating for the company in a research report on Tuesday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Prothena in a research report on Wednesday, March 13th. Finally, JMP Securities raised their target price on Prothena from $81.00 to $85.00 and gave the company a "market outperform" rating in a research report on Friday, February 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $69.63.

Prothena Trading Down 3.0 %

The company has a market cap of $1.15 billion, a PE ratio of -7.62 and a beta of 0.21. The firm has a fifty day moving average of $26.33 and a two-hundred day moving average of $33.21.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.03). The company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative net margin of 160.91% and a negative return on equity of 24.84%. The firm's quarterly revenue was down 99.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.12 EPS. Sell-side analysts expect that Prothena Co. plc will post -4.89 EPS for the current fiscal year.

Insider Activity

In other news, CAO Karin L. Walker sold 5,000 shares of Prothena stock in a transaction dated Wednesday, January 24th. The stock was sold at an average price of $34.00, for a total transaction of $170,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 28.10% of the company's stock.

Institutional Trading of Prothena

A number of large investors have recently modified their holdings of the business. Wellington Management Group LLP lifted its position in Prothena by 21.1% in the 4th quarter. Wellington Management Group LLP now owns 2,594,102 shares of the biotechnology company's stock worth $94,270,000 after buying an additional 452,455 shares during the last quarter. Bank of America Corp DE lifted its position in Prothena by 363.9% in the first quarter. Bank of America Corp DE now owns 564,441 shares of the biotechnology company's stock valued at $27,358,000 after purchasing an additional 442,770 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Prothena by 10.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,237,351 shares of the biotechnology company's stock valued at $153,986,000 after purchasing an additional 417,338 shares during the last quarter. State Street Corp lifted its position in Prothena by 20.0% in the first quarter. State Street Corp now owns 2,367,583 shares of the biotechnology company's stock valued at $86,583,000 after purchasing an additional 394,633 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Prothena in the fourth quarter valued at approximately $10,103,000. Institutional investors own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.